Tempest Therapeutics develops cancer treatments, including immune cell therapies and small molecule drugs, for patients with blood cancers and solid tumors. TPST reports earnings on Wed, Nov 4, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 24 | HC Wainwright & Co. | Maintained | Buy |
Seasonality
How TPST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.
Whale Options Flow
90DNo whale options trades in TPST in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TPST is in one of them and how their past TPST trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TPST in an article yet. Here's the latest on the wider market.
About Tempest Therapeutics
Tempest Therapeutics is a biotechnology company based in Brisbane, California, that develops treatments for cancer. Its pipeline includes cell therapies that use engineered immune cells to target tumors, including a candidate for multiple myeloma, a blood cancer. It also develops small molecule drugs, including one being prepared for late-stage testing in liver cancer and another for people with a rare inherited condition that raises the risk of certain cancers. Its candidates are still in development and not approved for sale, and they are aimed at patients with these cancers and conditions.
- Headquarters
- Brisbane, CA